Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $4.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s target price indicates a potential upside of 388.16% from the stock’s current price.
A number of other equities research analysts also recently weighed in on LXRX. Needham & Company LLC restated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, December 23rd. Leerink Partners set a $6.00 target price on Lexicon Pharmaceuticals and gave the company an “outperform” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $5.00.
Read Our Latest Analysis on Lexicon Pharmaceuticals
Lexicon Pharmaceuticals Price Performance
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). The business had revenue of $1.75 million for the quarter, compared to analyst estimates of $3.14 million. Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. During the same quarter last year, the firm posted ($0.21) EPS. On average, research analysts expect that Lexicon Pharmaceuticals will post -0.66 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. FMR LLC grew its holdings in shares of Lexicon Pharmaceuticals by 28.9% in the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock worth $78,291,000 after acquiring an additional 11,179,919 shares during the last quarter. Point72 Asset Management L.P. increased its stake in Lexicon Pharmaceuticals by 605.2% in the 2nd quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock worth $6,924,000 after purchasing an additional 3,536,805 shares in the last quarter. Geode Capital Management LLC raised its holdings in Lexicon Pharmaceuticals by 8.4% during the 3rd quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock worth $5,534,000 after buying an additional 273,436 shares during the period. State Street Corp lifted its stake in Lexicon Pharmaceuticals by 6.8% during the third quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company’s stock valued at $3,880,000 after buying an additional 157,738 shares in the last quarter. Finally, Pinnacle Associates Ltd. boosted its holdings in shares of Lexicon Pharmaceuticals by 0.9% in the third quarter. Pinnacle Associates Ltd. now owns 1,730,821 shares of the biopharmaceutical company’s stock worth $2,648,000 after buying an additional 14,990 shares during the period. Institutional investors own 74.70% of the company’s stock.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.
Read More
- Five stocks we like better than Lexicon Pharmaceuticals
- How to Calculate Retirement Income: MarketBeat’s Calculator
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Do ETFs Pay Dividends? What You Need to Know
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.